Astellas Pharma, Inc. and Welldoc, Inc. currently collaborated to envisage for the development and commercialization of digital therapeutics. The CEOs of two healthcare giants have duly signed a licensing agreement of strategic partnership.
The agreement states that Astellas Pharma, Inc. and Welldoc, Inc. collaboration will develop healthcare solutions “BlueStar” formulated in Japan and other Asian Countries for patients’ lifestyle disorder-diabetes. The agreement further includes that the collaboration will raise revenue and expects royalty on any future product sale.
Food and Drug Administration (FDA) gave clearance to the “BlueStar” in the U.S. as a digital health solution for patients suffering from type 1diabetes and type 2diabetes. BlueStar not only helps to assist and manage the disease but also uses individual patient’s data supportive with machine learning that tailors diabetes self-management. In addition, BlueStar in the past got clearance from the FDA coupled with 6 additional clearances to date. In the U.S. BlueStar is marketed on prescription as well as non-prescription as a digital healthcare solution for diabetes management.
The CEO of the Welldoc, Inc. said that Welldoc is excited and proud to be associated as a strategic partner with Astellas, Pharma Inc. with a similar vision and commitment to improving the health of people suffering from chronic diseases. Astellas will withstand as a critical partner as committed with future developments and advances to offer clinically relevant healthcare solutions.
The CFO of Astellas said, “Astellas is committed to developing Rx+TM programs and clinically relevant healthcare solutions (Rx+TM) that couples with a combination of expertise gained from prescription drug business with technology and knowledge from different healthcare fields”. Furthermore, the Vice President concluded that “technological advancements in digital technology are bringing diverse changes and innovations in healthcare fields and Astellas is on the upfront to invest and active for the dynamic changes for integration in the industry”.